Hanmi Pharm to Sue Han Jong-hoon, CEO of Hanmi Science, for Defamation

Hanmi Science, Recently Filing Complaints Against Hanmi Pharm Executives One After Another

Hanmi Pharm has announced its intention to file a complaint against key figures including Lim Jong-hoon, CEO of its holding company Hanmi Science, on charges of false accusation, obstruction of business, and breach of trust. This move follows Hanmi Science's recent complaint against Hanmi Pharm's management for breach of trust and other charges.

On the 20th, Hanmi Pharm stated in a press release, "Hanmi Science has been repeatedly filing complaints against our employees," and claimed, "These complaints are attempts to influence the upcoming extraordinary general meeting of shareholders."

It added, "Due to distorted information affecting shareholders, we are submitting a complaint for the first time," and "We will file a complaint against CEO Lim and related parties for false accusation, as well as submit complaints against Hanmi Science for obstruction of business, breach of trust, and other charges that have been ongoing for months."

Previously, Hanmi Science had filed complaints against Hanmi Pharm's management consecutively. On the 18th, it filed charges of breach of trust and embezzlement against CEO Park Jae-hyun and other executives, and last week, it sued the three-party coalition consisting of Song Young-sook, Chairwoman of Hanmi Pharm Group, Vice Chairman Lim Joo-hyun, and Shin Dong-guk, Chairman of Hanyang Precision and the largest individual shareholder, on charges of coercion and obstruction of business. On the 13th, Hanmi Science director Lim Jong-yoon, whose largest shareholder is the Kori Group, filed a complaint against Han Seong-jun, CEO of Kori Group, accusing Chairwoman Song and CEO Park of violating the Act on the Aggravated Punishment of Specific Economic Crimes (breach of trust).

Currently, Hanmi Pharm Group is embroiled in a conflict over the overall management control between the Lim brothers?Lim Jong-yoon, an inside director of Hanmi Science holding management rights of the holding company, and CEO Lim Jong-hoon?and the three-party coalition advocating for the introduction of a professional management system and demanding a reorganization of the holding company's board of directors.

The three-party coalition and the Lim brothers will face off in a vote on issues such as expanding the number of directors and appointing new directors at the Hanmi Science extraordinary general meeting of shareholders scheduled for the 28th. On the 19th of next month, an extraordinary general meeting of Hanmi Pharm shareholders will be held to discuss the agenda including the dismissal of CEO Park.

This content was produced with the assistance of AI translation services.